Celldex Therapeutics Inc CLDX
News
Celldex Announces Upcoming Late Breaking Oral Presentation of 52 Week Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EADV Congress 2024
Celldex Therapeutics to Present at Upcoming Investor Conferences
Celldex Reports Second Quarter 2024 Financial Results and Provides Corporate Update
Celldex Therapeutics Presents Positive Topline Results from Barzolvolimab Phase 2 Study in Chronic Inducible Urticaria
Celldex Therapeutics Initiates Global Phase 3 Program for Barzolvolimab in Patients with Chronic Spontaneous Urticaria
Celldex Therapeutics shares surge as lead asset shows promise in two skin conditions